Cargando…

A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients

BACKGROUND AND AIMS: Most data on liver assessment in type 2 diabetes mellitus (T2DM) patients are from retrospective cohorts with selection bias. We aimed at appraising the feasibility, results, and benefits of an outpatient systematic noninvasive screening for metabolic dysfunction-associated fatt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Binet, Quentin, Loumaye, Audrey, Hermans, Michel P, Lanthier, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500296/ https://www.ncbi.nlm.nih.gov/pubmed/37719967 http://dx.doi.org/10.14218/JCTH.2023.00117

Ejemplares similares

Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
por: Lanthier, Nicolas, et al.
Publicado: (2022)

Fructoholism in adults: The importance of personalised care in metabolic dysfunction-associated fatty liver disease
por: Salavrakos, Mélissa, et al.
Publicado: (2021)

Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Hwang, Tae-In, et al.
Publicado: (2021)

Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction
por: Valenti, Luca, et al.
Publicado: (2022)

Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19
por: Sharma, Praveen, et al.
Publicado: (2020)

Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease
por: Huang, Jee-Fu, et al.
Publicado: (2023)

Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models
por: Depommier, Clara, et al.
Publicado: (2021)

Prevalence of fatty liver in metabolic syndrome
por: Goyal, Anita, et al.
Publicado: (2020)

Metabolic dysfunction-associated fatty liver disease in people living with HIV
por: Michel, Maurice, et al.
Publicado: (2023)

Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
por: Vasques-Monteiro, Isabela Macedo Lopes, et al.
Publicado: (2021)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Han, Eugene, et al.
Publicado: (2022)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome
por: Depommier, Clara, et al.
Publicado: (2021)

Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
por: Binet, Quentin, et al.
Publicado: (2018)

Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease
por: Semmler, Georg, et al.
Publicado: (2020)

Racial differences in prevalence and severity of non-alcoholic fatty liver disease
por: Bonacini, Maurizio, et al.
Publicado: (2021)

The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
por: Martín-Mateos, Rosa, et al.
Publicado: (2021)

High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease
por: Zhu, Cuiling, et al.
Publicado: (2022)

Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults
por: Shi, Ameng, et al.
Publicado: (2023)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
por: Lee, Jung Il
Publicado: (2022)

Therapeutic developments in metabolic dysfunction-associated fatty liver disease
por: Shi, Yiwen, et al.
Publicado: (2022)

Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
por: Perdomo, Carolina M., et al.
Publicado: (2022)

Postprandial dysfunction in fatty liver disease
por: Grandt, Josephine, et al.
Publicado: (2023)

High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Fetuin-A in Activated Liver Macrophages Is a Key Feature of Non-Alcoholic Steatohepatitis
por: Etienne, Quentin, et al.
Publicado: (2022)

Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus
por: Miyake, Teruki, et al.
Publicado: (2022)

Perception of Non-Alcoholic Fatty Liver Disease: Real-Life Experience From Pakistan
por: Butt, Nazish, et al.
Publicado: (2021)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease
por: Machado, Mariana Verdelho
Publicado: (2021)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease
por: Lin, Huapeng, et al.
Publicado: (2021)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

Implications of metabolic dysfunction associated fatty liver disease in COVID-19
por: Chakraborty, Raja, et al.
Publicado: (2023)

Non-invasive assessment of metabolic dysfunction–associated fatty liver disease
por: Chandra Kumar, C. Vikneshwaran, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
por: Song, Byeong Geun, et al.
Publicado: (2023)

Mitochondrial Dysfunction and Acute Fatty Liver of Pregnancy
por: Ramanathan, Raghu, et al.
Publicado: (2022)

Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19
por: Targher, G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r9inutgk6k7ucp1d2ikmo9ull9